Novo Nordisks Semaglutide Delivers In Phase 3 MASH Study, Teeing Up Filings
1, 2024, 10:50 am. Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the soul trial. Novo intends to seek approvals of semaglutide in mash in the u. s. And europe in the first half of 2025. “we are very pleased about the essence clinical trial results and the.
Novo nordisk's semaglutide delivers in phase 3 mash study, teeing up filings by fraiser kansteiner nov 1, 2024 10:38am novo nordisk semaglutide mash. Semaglutide 2. 4 mg demonstrates superior improvement in both liver fibrosis and mash resolution in the essence trial. The mean change in body weight from baseline to week 68 was −13. 7% with semaglutide and −3. 2% with placebo (p (novo nordisk) designed the trial,.